Enanta Lands $42.7M in NIAID Funds for Bicyclolide Antibiotic
By Catherine Shaffer
Friday, October 14, 2011
Enanta Pharmaceuticals Inc. is banking on bicyclolides with a new $42.7 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) to support five years of development of the drugs as medical countermeasures against biodefense category A and B bacteria.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.